Product Information
REYVOW 100 MG TABLET is a brand product labeled by Eli Lilly and Company, priced at $88.7715 per EA under NDC 00002449108. Its NADAC has been published 327 times since May 20, 2020.
FDA first approved this application on Jan 31, 2020.
Strength
100 mg/1
Manufacturer
Eli Lilly and CompanyNDC
00002449108
Classification
Brand
Dosage Form
TABLET
Route
ORAL
Effective Date
5/20/2026
Active Ingredients
LASMIDITANApproval Type
New Drug (NDA)
FDA Application
NDA211280FDA Approved
1/31/2020
On Market Since
10/11/2019
Price Statistics
The NADAC for REYVOW 100 MG TABLET has been published 327 times since May 20, 2020, and over the history we have for it it has risen 15.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $88.7715 per EA |
|---|---|
| All-time high | $88.8816 (Apr 16, 2025) |
| All-time low | $77.0880 (May 20, 2020) |
| 52-week high | $88.8688 |
| 52-week low | $88.7715 |
| Median price | $88.6185 |
| Average price | $85.5843 |
| Largest weekly change | +5.0% (Jan 12, 2022) |
| Weeks tracked | 327 |
| Tracking since | May 20, 2020 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the lasmiditan market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of REYVOW 100 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for REYVOW 100 MG TABLET, manufactured by Eli Lilly and Company, is $88.7715 per EA (NDC 00002449108), effective Aug 19, 2026.
How has the price of REYVOW 100 MG TABLET changed over time?
Over the history we have for it, the NADAC for REYVOW 100 MG TABLET has risen 15.2%. It has been tracked across 327 weekly CMS publications since May 20, 2020.
What are the highest and lowest recorded NADAC prices for REYVOW 100 MG TABLET?
Since May 20, 2020, the NADAC for REYVOW 100 MG TABLET has ranged from a low of $77.0880 (May 20, 2020) to a high of $88.8816 (Apr 16, 2025), with a median of $88.6185 per EA.
Are there cheaper alternatives to REYVOW 100 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of REYVOW 100 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures REYVOW 100 MG TABLET?
REYVOW 100 MG TABLET (NDC 00002449108) is labeled by Eli Lilly and Company, and CMS classifies it as a brand product.